A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab
Histiocytic sarcoma (HS) is a rare disease with a poor prognosis. The efficacy of immune checkpoint inhibitors for this disease has not been established. A 13-year-old boy with HS refractory to conventional chemotherapy was treated with pembrolizumab, an immune checkpoint inhibitor. After treatment,...
Gespeichert in:
| Veröffentlicht in: | International cancer conference journal 2022-10, Vol.11 (4), p.280-285 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 285 |
|---|---|
| container_issue | 4 |
| container_start_page | 280 |
| container_title | International cancer conference journal |
| container_volume | 11 |
| creator | Furui, Yu Kurata, Takashi Komori, Kazutoshi Uchida, Eriko Miyairi, Yosuke Chiba, Akihiro Ogiso, Yoshifumi Sakashita, Kazuo |
| description | Histiocytic sarcoma (HS) is a rare disease with a poor prognosis. The efficacy of immune checkpoint inhibitors for this disease has not been established. A 13-year-old boy with HS refractory to conventional chemotherapy was treated with pembrolizumab, an immune checkpoint inhibitor. After treatment, the primary lesion and the bone metastases showed improvement; however, new metastatic lesions also occurred. This case suggests that the effect of immune checkpoint inhibitors might depend not only on programmed death ligand-1 expression and the ratio of tumor mutational burden, but also on other factors, such as the tumor microenvironment. Evaluation of more cases is required to identify biomarkers that define the efficacy of immune checkpoint inhibitors. |
| doi_str_mv | 10.1007/s13691-022-00562-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9522943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2919735803</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-7f1cd020d850d5357bb7dc43f702d2a5e61681a0d1999e00af39e1096e3037cb3</originalsourceid><addsrcrecordid>eNp9kUtPAjEUhRujEYL8ARemievR25Z5dGNCiK-ExI1ubTqdDpQwFNsOgr_eIoi6cdWb3nPPPe2H0DmBKwKQX3vCMk4SoDQBSDOarI9QlxJOE0YKdvyr7qC-9zMAoDDgUGSnqMMyUmSU0i56HWIlvca2xk6r1jm9CLGqnVTBug1W2q2MknO8dKaR8WJqfDBWbYJR2EunbCNxcFoGXeF3E6Z4qZvS2bn5aBtZnqGTWs697u_PHnq5u30ePSTjp_vH0XCcKMbTkOQ1UVXMVxUpVClL87LMKzVgdQ60ojLVGckKIqEinHMNIGvGNQGeaQYsVyXroZud77ItG12p-Aon52IfWlhpxN_OwkzFxK4ETynlAxYNLvcGzr612gcxs61bxMyCcsJzlhawVdGdSjnrffymwwYCYotF7LCIiEV8YRHrOHTxO9th5BtCFLCdwMfWYqLdz-5_bD8BBPOa5w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2919735803</pqid></control><display><type>article</type><title>A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab</title><source>ProQuest Central (Alumni Edition)</source><source>SpringerNature Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>PubMed Central</source><source>ProQuest Central</source><creator>Furui, Yu ; Kurata, Takashi ; Komori, Kazutoshi ; Uchida, Eriko ; Miyairi, Yosuke ; Chiba, Akihiro ; Ogiso, Yoshifumi ; Sakashita, Kazuo</creator><creatorcontrib>Furui, Yu ; Kurata, Takashi ; Komori, Kazutoshi ; Uchida, Eriko ; Miyairi, Yosuke ; Chiba, Akihiro ; Ogiso, Yoshifumi ; Sakashita, Kazuo</creatorcontrib><description>Histiocytic sarcoma (HS) is a rare disease with a poor prognosis. The efficacy of immune checkpoint inhibitors for this disease has not been established. A 13-year-old boy with HS refractory to conventional chemotherapy was treated with pembrolizumab, an immune checkpoint inhibitor. After treatment, the primary lesion and the bone metastases showed improvement; however, new metastatic lesions also occurred. This case suggests that the effect of immune checkpoint inhibitors might depend not only on programmed death ligand-1 expression and the ratio of tumor mutational burden, but also on other factors, such as the tumor microenvironment. Evaluation of more cases is required to identify biomarkers that define the efficacy of immune checkpoint inhibitors.</description><identifier>ISSN: 2192-3183</identifier><identifier>EISSN: 2192-3183</identifier><identifier>DOI: 10.1007/s13691-022-00562-x</identifier><identifier>PMID: 36186222</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Abdomen ; Autoimmune diseases ; Biomarkers ; Brain cancer ; Case Report ; Cervical cancer ; Chemotherapy ; Immune checkpoint inhibitors ; Kinases ; Ligands ; Lymphatic system ; Lymphocytes ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Oncology ; Patients ; Pembrolizumab ; Sarcoma ; Surgical Oncology ; Tomography ; Tumor microenvironment ; Tumors</subject><ispartof>International cancer conference journal, 2022-10, Vol.11 (4), p.280-285</ispartof><rights>The Author(s) under exclusive licence to The Japan Society of Clinical Oncology 2022</rights><rights>The Author(s) under exclusive licence to The Japan Society of Clinical Oncology 2022.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-7f1cd020d850d5357bb7dc43f702d2a5e61681a0d1999e00af39e1096e3037cb3</citedby><cites>FETCH-LOGICAL-c395t-7f1cd020d850d5357bb7dc43f702d2a5e61681a0d1999e00af39e1096e3037cb3</cites><orcidid>0000-0002-7331-7952</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522943/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2919735803?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,21388,21389,27924,27925,33530,33744,41488,42557,43659,43805,51319,53791,53793,64385,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36186222$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Furui, Yu</creatorcontrib><creatorcontrib>Kurata, Takashi</creatorcontrib><creatorcontrib>Komori, Kazutoshi</creatorcontrib><creatorcontrib>Uchida, Eriko</creatorcontrib><creatorcontrib>Miyairi, Yosuke</creatorcontrib><creatorcontrib>Chiba, Akihiro</creatorcontrib><creatorcontrib>Ogiso, Yoshifumi</creatorcontrib><creatorcontrib>Sakashita, Kazuo</creatorcontrib><title>A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab</title><title>International cancer conference journal</title><addtitle>Int Canc Conf J</addtitle><addtitle>Int Cancer Conf J</addtitle><description>Histiocytic sarcoma (HS) is a rare disease with a poor prognosis. The efficacy of immune checkpoint inhibitors for this disease has not been established. A 13-year-old boy with HS refractory to conventional chemotherapy was treated with pembrolizumab, an immune checkpoint inhibitor. After treatment, the primary lesion and the bone metastases showed improvement; however, new metastatic lesions also occurred. This case suggests that the effect of immune checkpoint inhibitors might depend not only on programmed death ligand-1 expression and the ratio of tumor mutational burden, but also on other factors, such as the tumor microenvironment. Evaluation of more cases is required to identify biomarkers that define the efficacy of immune checkpoint inhibitors.</description><subject>Abdomen</subject><subject>Autoimmune diseases</subject><subject>Biomarkers</subject><subject>Brain cancer</subject><subject>Case Report</subject><subject>Cervical cancer</subject><subject>Chemotherapy</subject><subject>Immune checkpoint inhibitors</subject><subject>Kinases</subject><subject>Ligands</subject><subject>Lymphatic system</subject><subject>Lymphocytes</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Oncology</subject><subject>Patients</subject><subject>Pembrolizumab</subject><subject>Sarcoma</subject><subject>Surgical Oncology</subject><subject>Tomography</subject><subject>Tumor microenvironment</subject><subject>Tumors</subject><issn>2192-3183</issn><issn>2192-3183</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kUtPAjEUhRujEYL8ARemievR25Z5dGNCiK-ExI1ubTqdDpQwFNsOgr_eIoi6cdWb3nPPPe2H0DmBKwKQX3vCMk4SoDQBSDOarI9QlxJOE0YKdvyr7qC-9zMAoDDgUGSnqMMyUmSU0i56HWIlvca2xk6r1jm9CLGqnVTBug1W2q2MknO8dKaR8WJqfDBWbYJR2EunbCNxcFoGXeF3E6Z4qZvS2bn5aBtZnqGTWs697u_PHnq5u30ePSTjp_vH0XCcKMbTkOQ1UVXMVxUpVClL87LMKzVgdQ60ojLVGckKIqEinHMNIGvGNQGeaQYsVyXroZud77ItG12p-Aon52IfWlhpxN_OwkzFxK4ETynlAxYNLvcGzr612gcxs61bxMyCcsJzlhawVdGdSjnrffymwwYCYotF7LCIiEV8YRHrOHTxO9th5BtCFLCdwMfWYqLdz-5_bD8BBPOa5w</recordid><startdate>202210</startdate><enddate>202210</enddate><creator>Furui, Yu</creator><creator>Kurata, Takashi</creator><creator>Komori, Kazutoshi</creator><creator>Uchida, Eriko</creator><creator>Miyairi, Yosuke</creator><creator>Chiba, Akihiro</creator><creator>Ogiso, Yoshifumi</creator><creator>Sakashita, Kazuo</creator><general>Springer Nature Singapore</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7331-7952</orcidid></search><sort><creationdate>202210</creationdate><title>A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab</title><author>Furui, Yu ; Kurata, Takashi ; Komori, Kazutoshi ; Uchida, Eriko ; Miyairi, Yosuke ; Chiba, Akihiro ; Ogiso, Yoshifumi ; Sakashita, Kazuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-7f1cd020d850d5357bb7dc43f702d2a5e61681a0d1999e00af39e1096e3037cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Abdomen</topic><topic>Autoimmune diseases</topic><topic>Biomarkers</topic><topic>Brain cancer</topic><topic>Case Report</topic><topic>Cervical cancer</topic><topic>Chemotherapy</topic><topic>Immune checkpoint inhibitors</topic><topic>Kinases</topic><topic>Ligands</topic><topic>Lymphatic system</topic><topic>Lymphocytes</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Oncology</topic><topic>Patients</topic><topic>Pembrolizumab</topic><topic>Sarcoma</topic><topic>Surgical Oncology</topic><topic>Tomography</topic><topic>Tumor microenvironment</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Furui, Yu</creatorcontrib><creatorcontrib>Kurata, Takashi</creatorcontrib><creatorcontrib>Komori, Kazutoshi</creatorcontrib><creatorcontrib>Uchida, Eriko</creatorcontrib><creatorcontrib>Miyairi, Yosuke</creatorcontrib><creatorcontrib>Chiba, Akihiro</creatorcontrib><creatorcontrib>Ogiso, Yoshifumi</creatorcontrib><creatorcontrib>Sakashita, Kazuo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International cancer conference journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Furui, Yu</au><au>Kurata, Takashi</au><au>Komori, Kazutoshi</au><au>Uchida, Eriko</au><au>Miyairi, Yosuke</au><au>Chiba, Akihiro</au><au>Ogiso, Yoshifumi</au><au>Sakashita, Kazuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab</atitle><jtitle>International cancer conference journal</jtitle><stitle>Int Canc Conf J</stitle><addtitle>Int Cancer Conf J</addtitle><date>2022-10</date><risdate>2022</risdate><volume>11</volume><issue>4</issue><spage>280</spage><epage>285</epage><pages>280-285</pages><issn>2192-3183</issn><eissn>2192-3183</eissn><abstract>Histiocytic sarcoma (HS) is a rare disease with a poor prognosis. The efficacy of immune checkpoint inhibitors for this disease has not been established. A 13-year-old boy with HS refractory to conventional chemotherapy was treated with pembrolizumab, an immune checkpoint inhibitor. After treatment, the primary lesion and the bone metastases showed improvement; however, new metastatic lesions also occurred. This case suggests that the effect of immune checkpoint inhibitors might depend not only on programmed death ligand-1 expression and the ratio of tumor mutational burden, but also on other factors, such as the tumor microenvironment. Evaluation of more cases is required to identify biomarkers that define the efficacy of immune checkpoint inhibitors.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>36186222</pmid><doi>10.1007/s13691-022-00562-x</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-7331-7952</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2192-3183 |
| ispartof | International cancer conference journal, 2022-10, Vol.11 (4), p.280-285 |
| issn | 2192-3183 2192-3183 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9522943 |
| source | ProQuest Central (Alumni Edition); SpringerNature Journals; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; PubMed Central; ProQuest Central |
| subjects | Abdomen Autoimmune diseases Biomarkers Brain cancer Case Report Cervical cancer Chemotherapy Immune checkpoint inhibitors Kinases Ligands Lymphatic system Lymphocytes Medicine Medicine & Public Health Metastases Metastasis Oncology Patients Pembrolizumab Sarcoma Surgical Oncology Tomography Tumor microenvironment Tumors |
| title | A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T12%3A31%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20case%20of%20recurrent%20refractory%20cervical%20primary%20histiocytic%20sarcoma%20treated%20with%20pembrolizumab&rft.jtitle=International%20cancer%20conference%20journal&rft.au=Furui,%20Yu&rft.date=2022-10&rft.volume=11&rft.issue=4&rft.spage=280&rft.epage=285&rft.pages=280-285&rft.issn=2192-3183&rft.eissn=2192-3183&rft_id=info:doi/10.1007/s13691-022-00562-x&rft_dat=%3Cproquest_pubme%3E2919735803%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2919735803&rft_id=info:pmid/36186222&rfr_iscdi=true |